Oligoovulatory and anovulatory cycles in women with polycystic ovary syndrome (PCOS): what's the difference?

J Clin Endocrinol Metab. 2010 Dec;95(12):E485-9. doi: 10.1210/jc.2009-2717. Epub 2010 Sep 15.

Abstract

Context: Polycystic ovary syndrome (PCOS) is a heterogeneous disorder. The phenotype may differ between patients who exhibit signs of recent ovulation and anovulatory PCOS patients.

Objective: Our objective was to study differences in clinical and endocrine characteristics and response to ovulation induction (OI) treatment comparing oligoovulatory and anovulatory PCOS patients.

Design and setting: We conducted a retrospective cohort study at a tertiary hospital.

Patients: PCOS patients (n=1750) presenting with oligo- or amenorrhea were diagnosed according to the Rotterdam 2003 consensus criteria. Arbitrarily, oligoovulatory PCOS was defined by a single random serum progesterone level of 10 nmol/liter or higher.

Main outcome measures: We evaluated the incidence of oligo- or amenorrhea, menstrual cycle length, serum androgen levels, follicle count, and OI outcome parameters.

Results: Anovulatory women (n=1541 of 1750, 88.1%) were more often amenorrheic (P<0.001) and presented with a longer cycle duration (P<0.001) compared with oligoovulatory women (n=209 of 1750, 11.9%). Serum levels of testosterone (P<0.001), the free androgen index (P<0.001), and total follicle count (P<0.005) were higher in anovulatory compared with oligoovulatory patients. During clomiphene citrate OI, more oligoovulatory women gained regular menstrual cycles (P<0.05), whereas after second-line treatment with recombinant FSH, more anovulatory women became pregnant (P<0.05).

Conclusions: Oligoovulatory women with PCOS exhibit a milder phenotype of ovarian dysfunction and have a more favorable response to OI treatment using clomiphene citrate compared with anovulatory PCOS patients. However, during second-line treatment with recombinant FSH, anovulatory PCOS patients presented with a higher chance of pregnancy compared with oligoovulatory patients.

MeSH terms

  • Adolescent
  • Adult
  • Amenorrhea / physiopathology
  • Androgens / blood
  • Anovulation / blood
  • Anovulation / drug therapy
  • Anovulation / genetics
  • Anovulation / physiopathology*
  • Clomiphene / therapeutic use
  • Cohort Studies
  • Female
  • Fertility Agents, Female / therapeutic use
  • Follicle Stimulating Hormone / therapeutic use
  • Humans
  • Menstrual Cycle / physiology
  • Ovulation Induction / methods
  • Ovulation Inhibition / physiology*
  • Phenotype
  • Polycystic Ovary Syndrome / complications
  • Polycystic Ovary Syndrome / drug therapy
  • Polycystic Ovary Syndrome / genetics
  • Polycystic Ovary Syndrome / physiopathology*
  • Pregnancy
  • Recombinant Proteins / therapeutic use
  • Retrospective Studies

Substances

  • Androgens
  • Fertility Agents, Female
  • Recombinant Proteins
  • Clomiphene
  • Follicle Stimulating Hormone